Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
Promising mid-stage data with Merck KGaA’s evobrutinib in multiple sclerosis could help the German group carve out a niche for its BTK inhibitor – unless bigger players…
Celgene’s surprise termination of a clinical trial makes for a day of soul-searching among other followers of the anti-CD47 approach.
The company’s Unity-CLL trial fails to yield an improvement in overall response, and investors should ask themselves whether the whole study is now doomed.
The company’s stock slides 12% on fears that the goalposts in its all-important Unity-CLL trial are being moved.
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
TG and Redhill are expecting phase III data soon, but both have a fight ahead to make their mark even if their projects succeed.